• Nasus Pharma will hold its annual and special general meeting of shareholders in Tel Aviv, Israel on Oct. 8, 2026.
• Votes will cover reappointing Deloitte Israel as independent auditor, with the board set to determine remuneration.
• Shareholders will also vote on reappointing directors David Silberman and Sharon Shacham for new three-year terms.
• Items include approval of CEO Brendan P. O’Grady’s compensation package, including US$500,000 base salary and up to 280,000 options.
• Additional votes include a US$70,000 one-time bonus for former CEO Dan Teleman, plus a higher share reserve for incentive stock options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-041534), on September 04, 2026, and is solely responsible for the information contained therein.